Celanese
CELANESE CORPORATION
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$9.5B
Operating marginCalculated
-8.2%
Net assets to total assetsCalculated
18.7%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★☆☆☆☆position among all companies
-8.2%
Growth (revenue, 4-year average)
★★☆☆☆position among all companies
2.8%
Capital efficiency
★☆☆☆☆position among all companies
-28.8%
Revenue and profit
Performance, financial position and capital allocation
Celanese
Recent performance trends
Celanese
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$8.5 billion | US$9.7 billion | US$10.9 billion | US$10.3 billion | US$9.5 billion |
| Operating income | US$1.9 billion | US$1.4 billion | US$1.7 billion | US$-0.7 billion | US$-0.8 billion |
| Net income | US$1.9 billion | US$1.9 billion | US$1.9 billion | US$-1.5 billion | US$-1.2 billion |
| Total assets | US$12.0 billion | US$26.3 billion | US$26.6 billion | US$22.8 billion | US$21.7 billion |
| Shareholders' equity | US$4.2 billion | US$5.6 billion | US$7.1 billion | US$5.1 billion | US$4.0 billion |
| Net cash provided by (used in) operating activities | US$1.8 billion | US$1.8 billion | US$1.9 billion | US$1.0 billion | US$1.1 billion |
| Net cash provided by (used in) investing activities | US$-1.1 billion | US$-11.1 billion | US$-0.1 billion | US$-0.5 billion | US$-0.3 billion |
| Net cash provided by (used in) financing activities | US$-1.0 billion | US$10.3 billion | US$-1.5 billion | US$-1.3 billion | US$-0.5 billion |
| Cash and cash equivalents | US$0.5 billion | US$1.5 billion | US$1.8 billion | US$1.0 billion | US$1.3 billion |
Revenue scale in the same industry
Celanese
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 21 companies
- 25 International Flavors & FragrancesFY Dec 2025 US$10.9B
- 26 BiogenFY Dec 2025 US$9.9B
- 27 CelaneseThis companyFY Dec 2025 US$9.5B
- 28 ZoetisFY Dec 2025 US$9.5B
- 29 Eastman ChemicalFY Dec 2025 US$8.8B
- … 27 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.3 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$1.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$1.1 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.8 billion | Consolidated | Disclosed |
| Dividends paid | US$13.00 million | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$4.5 billion | Consolidated | Disclosed |
| Non-controlling interests | US$0.4 billion | Consolidated | Disclosed |
| Net assets | US$4.0 billion | Consolidated | Disclosed |
| Net sales | US$9.5 billion | Consolidated | Disclosed |
| Operating income | US$-0.8 billion | Consolidated | Disclosed |
| Net income | US$-1.2 billion | Consolidated | Disclosed |
| Total assets | US$21.7 billion | Consolidated | Disclosed |
| Operating margin | -8.2% | Consolidated | Calculated |
| Net assets to total assets | 18.7% | Consolidated | Calculated |
| Net margin | -12.2% | Consolidated | Calculated |
| Return on equity | -28.8% | Consolidated | Calculated |